Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

多叶素VII是一种通过STAT3信号通路靶向肝细胞癌干性的潜在药物

卷 23, 期 4, 2023

发表于: 10 November, 2022

页: [325 - 331] 页: 7

弟呕挨: 10.2174/1568009623666221024103834

价格: $65

摘要

背景:目前，肝细胞癌(HCC)的治疗受到残余肝癌干细胞(CSCs)引起的治疗失败和复发的干扰。因此，靶向HCC CSCs的药物应该能够有效地消除HCC并防止其复发。在本研究中，我们证实了Polyphyllin VII (PP7)对HCC CSCs的作用，并探讨了其可能的机制。 方法:采用HepG2和Huh7细胞，通过定量细胞生长和转移来分析PP7的抗肿瘤活性，并研究其对干性的影响。 结果:PP7促进HepG2和Huh7细胞凋亡，显著抑制细胞增殖和迁移。PP7还能抑制肿瘤球体的形成，并诱导茎性标志物(CD133和OCT-4)的表达发生显著变化。PP7的这些作用是由STAT3信号通路介导的。 结论:PP7可通过调控STAT3信号通路有效抑制肝癌细胞的起始、生长和转移，抑制肝癌细胞干性。我们的数据将为进一步阐明PP7对HCC的治疗作用提供更多的证据。

关键词: PP7，肝细胞癌，癌干细胞，STAT3信号通路，CD133, OCT-4。

« Previous
图形摘要

[1]
Chen, W.; Zheng, R.; Baade, P.D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer statistics in China, 2015. CA Cancer J. Clin., 2016, 66(2), 115-132.
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[2]
Hernandez, G.V.; Toffanin, S.; Friedman, S.L.; Llovet, J.M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology, 2013, 144(3), 512-527.
[http://dx.doi.org/10.1053/j.gastro.2013.01.002] [PMID: 23313965]
[3]
Garg, M. Epithelial plasticity and cancer stem cells: Major mechanisms of cancer pathogenesis and therapy resistance. World J. Stem Cells, 2017, 9(8), 118-126.
[http://dx.doi.org/10.4252/wjsc.v9.i8.118] [PMID: 28928908]
[4]
Chai, S.; Ng, K.Y.; Tong, M.; Lau, E.Y.; Lee, T.K.; Chan, K.W.; Yuan, Y.F.; Cheung, T.T.; Cheung, S.T.; Wang, X.Q.; Wong, N.; Lo, C.M.; Man, K.; Guan, X.Y.; Ma, S. Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology, 2016, 64(6), 2062-2076.
[http://dx.doi.org/10.1002/hep.28821] [PMID: 27639189]
[5]
Di, J.; De Boer, D.T.; Zusterzeel, P.L.M.; Figdor, C.G.; Massuger, L.F.A.G.; Torensma, R. The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients. Cell. Oncol., 2013, 36(5), 363-374.
[http://dx.doi.org/10.1007/s13402-013-0142-8] [PMID: 23928726]
[6]
Sainz, B., Jr; Alcala, S.; Garcia, E.; Sanchez, R.Y.; Azevedo, M.M.; Cioffi, M.; Tatari, M.; Miranda, L.I.; Hidalgo, M.; Gomez, L.G.; Cañamero, M.; Erkan, M.; Kleeff, J.; García, S.S.; Sancho, P.; Hermann, P.C.; Heeschen, C. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut, 2015, 64(12), 1921-1935.
[http://dx.doi.org/10.1136/gutjnl-2014-308935] [PMID: 25841238]
[7]
Myung, S.J.; Yoon, J.H.; Yu, S.J. STAT3 & cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. Biomed. Pharmacother., 2012, 66(8), 612-616.
[http://dx.doi.org/10.1016/j.biopha.2012.08.011] [PMID: 23089473]
[8]
Gariboldi, M.B.; Ravizza, R.; Molteni, R.; Osella, D.; Gabano, E.; Monti, E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett., 2007, 258(2), 181-188.
[http://dx.doi.org/10.1016/j.canlet.2007.08.019] [PMID: 17920763]
[9]
Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J.B.; Liotta, L.A.; Petricoin, E., III; Zhang, Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA, 2007, 104(41), 16158-16163.
[http://dx.doi.org/10.1073/pnas.0702596104] [PMID: 17911267]
[10]
Dragu, D.L.; Necula, L.G.; Bleotu, C.; Diaconu, C.C.; Chivu, E.M. Therapies targeting cancer stem cells: Current trends and future challenges. World J. Stem Cells, 2015, 7(9), 1185-1201.
[PMID: 26516409]
[11]
Wang, H.; Zhai, Z.; Li, N.; Jin, H.; Chen, J.; Yuan, S.; Wang, L.; Zhang, J.; Li, Y.; Yun, J.; Fan, J.; Yi, J.; Ling, R. Steroidal saponin of Trillium tschonoskii. Reverses multidrug resistance of hepatocellular carcinoma. Phytomedicine, 2013, 20(11), 985-991.
[http://dx.doi.org/10.1016/j.phymed.2013.04.014] [PMID: 23786867]
[12]
Li, Z.H.; Wan, J.I.A.Y.U.; Wang, G.U.I.Q.I.N.; Zhao, F.G.; Wen, J.H. Identification of compounds from Paris polyphylla (ChongLou) active against Dactylogyrus intermedius. Parasitology, 2013, 140(8), 952-958.
[http://dx.doi.org/10.1017/S0031182013000139] [PMID: 23552446]
[13]
Yin, X.; Qu, C.; Li, Z.; Zhai, Y.; Cao, S.; Lin, L.; Feng, L.; Yan, L.; Ni, J. Simultaneous determination and pharmacokinetic study of polyphyllin I, polyphyllin II, polyphyllin VI and polyphyllin VII in beagle dog plasma after oral administration of Rhizoma paridis extracts by LC-MS-MS. Biomed. Chromatogr., 2013, 27(3), 343-348.
[PMID: 22903625]
[14]
Xiao, X.H.; Yuan, Z.Q.; Li, G.K. Separation and purification of steroidal saponins from Paris polyphylla by microwave-assisted extraction coupled with countercurrent chromatography using evaporative light scattering detection. J. Sep. Sci., 2014, 37(6), 635-641.
[http://dx.doi.org/10.1002/jssc.201301341] [PMID: 24772456]
[15]
Zhang, C.; Jia, X.; Wang, K.; Bao, J.; Li, P.; Chen, M.; Wan, J.B.; Su, H.; Mei, Z.; He, C. Polyphyllin VII induces an autophagic cell death by activation of the JNK pathway and inhibition of PI3K/AKT/mTOR pathway in HepG2 cells. PLoS One, 2016, 11(1)e0147405
[http://dx.doi.org/10.1371/journal.pone.0147405] [PMID: 26808193]
[16]
He, D.X.; Li, G.H.; Gu, X.T.; Zhang, L.; Mao, A.Q.; Wei, J.; Liu, D.Q.; Shi, G.Y.; Ma, X. A new agent developed by biotransformation of polyphyllin VII inhibits chemoresistance in breast cancer. Oncotarget, 2016, 7(22), 31814-31824.
[http://dx.doi.org/10.18632/oncotarget.6674] [PMID: 26701723]
[17]
Lin, Z.; Liu, Y.; Li, F.; Wu, J.; Zhang, G.; Wang, Y.; Lu, L.; Liu, Z. Anti-lung cancer effects of polyphyllin vi and vii potentially correlate with apoptosis in vitro and in vivo. Phytother. Res., 2015, 29(10), 1568-1576.
[http://dx.doi.org/10.1002/ptr.5430] [PMID: 26272214]
[18]
Fan, X.; Zhu, M.; Qiu, F.; Li, W.; Wang, M.; Guo, Y.; Xi, X.; Du, B. Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44. Int. Immunopharmacol., 2020, 88106991
[http://dx.doi.org/10.1016/j.intimp.2020.106991] [PMID: 33182071]
[19]
Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med., 2006, 355(12), 1253-1261.
[http://dx.doi.org/10.1056/NEJMra061808] [PMID: 16990388]
[20]
Zheng, H.C. The molecular mechanisms of chemoresistance in cancers. Oncotarget, 2017, 8(35), 59950-59964.
[http://dx.doi.org/10.18632/oncotarget.19048] [PMID: 28938696]
[21]
Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
[http://dx.doi.org/10.1038/nrc1590] [PMID: 15803154]
[22]
Dallas, N.A.; Xia, L.; Fan, F.; Gray, M.J.; Gaur, P.; Van Buren, G.I.I.; Samuel, S.; Kim, M.P.; Lim, S.J.; Ellis, L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res., 2009, 69(5), 1951-1957.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2023] [PMID: 19244128]
[23]
Lytle, N.K.; Ferguson, L.P.; Rajbhandari, N.; Gilroy, K.; Fox, R.G.; Deshpande, A.; Schürch, C.M.; Hamilton, M.; Robertson, N.; Lin, W.; Noel, P.; Wartenberg, M.; Zlobec, I.; Eichmann, M.; Galván, J.A.; Karamitopoulou, E.; Gilderman, T.; Esparza, L.A.; Shima, Y.; Spahn, P.; French, R.; Lewis, N.E.; Fisch, K.M.; Sasik, R.; Rosenthal, S.B.; Kritzik, M.; Von Hoff, D.; Han, H.; Ideker, T.; Deshpande, A.J.; Lowy, A.M.; Adams, P.D.; Reya, T. A multiscale map of the stem cell state in pancreatic adenocarcinoma. Cell, 2019, 177(3), 572-586.e22.
[http://dx.doi.org/10.1016/j.cell.2019.03.010] [PMID: 30955884]
[24]
Zhang, C.; Li, Q.; Qin, G.; Zhang, Y.; Li, C.; Han, L.; Wang, R.; Wang, S.; Chen, H.; Liu, K.; He, C. Anti-angiogenesis and anti-metastasis effects of polyphyllin VII on hepatocellular carcinoma cells in vitro and in vivo. Chin. Med., 2021, 16(1), 41.
[http://dx.doi.org/10.1186/s13020-021-00447-w] [PMID: 34059099]
[25]
Ahmad, B.; Rehman, S.U.; Azizullah, A.; Khan, M.F.; Din, S.R.U.; Ahmad, M.; Ali, A.; Tahir, N.; Azam, N.; Gamallat, Y.; Rahman, K.U.; Ali, M.; Safi, M.; Khan, I.; Qamer, S.; Oh, D.H. Molecular mechanisms of anticancer activities of polyphyllin VII. Chem. Biol. Drug Des., 2021, 97(4), 914-929.
[http://dx.doi.org/10.1111/cbdd.13818] [PMID: 33342040]
[26]
Feng, F.F.; Cheng, P.; Sun, C.; Wang, H.; Wang, W. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition. Chin. J. Nat. Med., 2019, 17(10), 768-777.
[http://dx.doi.org/10.1016/S1875-5364(19)30093-7] [PMID: 31703757]
[27]
He, H.; Xu, C.; Zheng, L.; Wang, K.; Jin, M.; Sun, Y.; Yue, Z. Polyphyllin VII induces apoptotic cell death via inhibition of the PI3K/Akt and NF-κB pathways in A549 human lung cancer cells. Mol. Med. Rep., 2020, 21(2), 597-606.
[PMID: 31974591]
[28]
Wang, P.; Yang, Q.; Du, X.; Chen, Y.; Zhang, T. Targeted regulation of Rell2 by microRNA-18a is implicated in the anti-metastatic effect of polyphyllin VI in breast cancer cells. Eur. J. Pharmacol., 2019, 851, 161-173.
[http://dx.doi.org/10.1016/j.ejphar.2019.02.041] [PMID: 30817902]
[29]
Jove, R. Preface: STAT signaling. Oncogene, 2000, 19(21), 2466-2467.
[http://dx.doi.org/10.1038/sj.onc.1203549] [PMID: 10851044]
[30]
Lee, T.K.W.; Castilho, A.; Cheung, V.C.H.; Tang, K.H.; Ma, S.; Ng, I.O.L. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell, 2011, 9(1), 50-63.
[http://dx.doi.org/10.1016/j.stem.2011.06.005] [PMID: 21726833]
[31]
Kasprzycka, M.; Marzec, M.; Liu, X.; Zhang, Q.; Wasik, M.A. Nucleophosmin/Anaplastic Lymphoma Kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl. Acad. Sci. USA, 2006, 103(26), 9964-9969.
[http://dx.doi.org/10.1073/pnas.0603507103] [PMID: 16766651]
[32]
Ren, D.; Lin, B.; Zhang, X.; Peng, Y.; Ye, Z.; Ma, Y.; Liang, Y.; Cao, L.; Li, X.; Li, R.; Sun, L.; Liu, Q.; Wu, J.; Zhou, K.; Zeng, J. Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget, 2017, 8(30), 49807-49823.
[http://dx.doi.org/10.18632/oncotarget.17971] [PMID: 28591704]
[33]
Niwa, H.; Burdon, T.; Chambers, I.; Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev., 1998, 12(13), 2048-2060.
[http://dx.doi.org/10.1101/gad.12.13.2048] [PMID: 9649508]
[34]
Chung, Y.J.; Park, B.B.; Kang, Y.J.; Kim, T.; Eaves, C.J.; Oh, I.H. Unique effects of Stat3 on the early phase of hematopoietic stem cell regeneration. Blood, 2006, 108(4), 1208-1215.
[http://dx.doi.org/10.1182/blood-2006-01-010199] [PMID: 16614239]
[35]
Kim, E.; Kim, M.; Woo, D.H.; Shin, Y.; Shin, J.; Chang, N.; Oh, Y.T.; Kim, H.; Rheey, J.; Nakano, I.; Lee, C.; Joo, K.M.; Rich, J.N.; Nam, D.H.; Lee, J. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell, 2013, 23(6), 839-852.
[http://dx.doi.org/10.1016/j.ccr.2013.04.008] [PMID: 23684459]
[36]
Kim, J.H.; Lee, S.C.; Ro, J.; Kang, H.S.; Kim, H.S.; Yoon, S. Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochem. Pharmacol., 2010, 79(3), 373-380.
[http://dx.doi.org/10.1016/j.bcp.2009.09.008] [PMID: 19766599]
[37]
Iliopoulos, D.; Hirsch, H.A.; Wang, G.; Struhl, K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA, 2011, 108(4), 1397-1402.
[http://dx.doi.org/10.1073/pnas.1018898108] [PMID: 21220315]

Rights & Permissions Print Cite
Article Metrics
38
2
© 2024 Bentham Science Publishers | Privacy Policy